Leaflet BOZILOS 14mg film-coated tablets


Indicated for: multiple sclerosis

Substance: teriflunomide (immunomodulator)

ATC: L04AA31 (Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants)

Teriflunomide is an immunomodulatory medication used for the treatment of relapsing multiple sclerosis. It works by inhibiting de novo pyrimidine synthesis, thereby reducing the activity of immune cells involved in the inflammatory process.

The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and undergo regular medical check-ups to monitor liver and hematological function.

Patients should be aware of potential side effects, such as nausea, diarrhea, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms or the use of other medications.

Common side effects include nausea, diarrhea, hair loss, and elevated liver enzymes. In rare cases, severe reactions such as hepatotoxicity or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about BOZILOS 14mg

  • Substance: teriflunomide
  • Date of last drug list: 01-05-2026
  • Commercial code: W69318001
  • Concentration: 14mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 28
  • Product type: generic
  • Price: 1736.89 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: PHARMADOX HEALTHCARE LIMITED - MALTA
  • Holder: EGIS PARMACEUTICALS PLC - UNGARIA
  • Number: 14812/2022/01
  • Shelf life: 30 months

Concentrations available for teriflunomide

  • 14mg
  • 7mg

Compensation lists for BOZILOS 14mg Egis

NHP 4.A (C2) - Multiple sclerosis

Price

Copayment

Patient

1736.89 RON

1491.30 RON

245.59 RON